Pipracil
(Piperacillin)ApprovedSmall molecule
Pipracil is one of 66 small molecule programs targeting Acute Kidney Injury. It is currently in Approved.
2
Indications
5
Total Trials
2
Active Trials
65
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
90 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Glypressin
MMallinckrodt
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Pipracil
WWyeth-Lederle Vaccines
Approved
Northera
LundbeckPhase 2
Lamisil
NovartisPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bacterial Pneumonia1 trial
Hematopoietic Stem Cell Transplantation1 trial
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Unknown status·—·N/A·NCT01714557·150 enrolled
Acute Kidney Injury1 trial
Liver1 trial
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial
Not yet recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT07759453·168 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PIPRACIL
NDA NDA050545
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Piperacillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- WWyeth-Lederle Vaccines